The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
76
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Local Institution - 0001
Miami, Florida, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to 21 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Time frame: Up to 21 days
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Time frame: Up to 21 days
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to 21 days
Apparent terminal phase half-life (T-HALF)
Time frame: Up to 21 days
Apparent total body clearance (CLT/F)
Time frame: Up to 21 days
Number of participants with adverse events (AEs)
Time frame: Up to 51 days
Number of participants with vital sign abnormalities
Time frame: Up to 51 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 51 days
Number of participants with physical examination abnormalities
Time frame: Up to 51 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 51 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days